Insider trade

Arrowhead Pharmaceuticals (ARWR)CFO sold ~$158K

Kenneth Allen Myszkowski, CFO at Arrowhead Pharmaceuticals, sold ~$158K of Arrowhead Pharmaceuticals shares.

~$158K
Approx. value · 8,000 sh @ $19.70: 465K
Holds after · shares reported

Traded: Jan 7, 2025
Filed: Jan 8, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Dec 16, 2024Insider · 3 peopleInsiders: 3 sales (~$389K)
Dec 17, 2024Insider · 2 peopleInsiders: 2 sales (~$95K)
Dec 18, 2024Insider · 1 personInsiders: 3 sales (~$567K)
Dec 23, 2024InsiderCEO sold ~$246K of ARWR shares in the open market
Dec 27, 2024InsiderDirector sold ~$57K of ARWR shares in the open market
Jan 2, 2025InsiderCEO sold ~$219K of ARWR shares in the open market
Jan 6, 2025Insider · 3 peopleInsiders: 6 sales (~$1.8M)
Jan 7, 2025 · this disclosureInsiderCFO sold ~$158K of ARWR shares in the open market

What came next

Jan 7, 2025Insider · 2 peopleInsiders: 2 sales (~$354K)
Jan 23, 2025InsiderDirector sold ~$20K of ARWR shares in the open market
Mar 3, 2025InsiderCEO sold ~$3.01M of ARWR shares in the open market
Mar 4, 2025InsiderCEO sold ~$2.27M of ARWR shares in the open market
Mar 13, 2025InsiderCEO sold ~$775K of ARWR shares in the open market
Apr 9, 2025Insider · 1 personInsiders: 3 sales (~$406K)
Apr 10, 2025InsiderCEO sold ~$544K of ARWR shares in the open market
Apr 11, 2025InsiderCEO sold ~$584K of ARWR shares in the open market

View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Arrowhead Pharmaceuticals

For Arrowhead Pharmaceuticals, OQRO holds 2 insider filings (SEC Form 4 or Form 144) and 9 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its ARWR page.

Other recent filings by Kenneth Allen Myszkowski, Chief Financial Officer

The full history of Kenneth Allen Myszkowski, Chief Financial Officer is on the profile page.

How this filing works

Other disclosures at Arrowhead Pharmaceuticals

Everything OQRO holds on this company is on its ARWR page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO Pro Already have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data